Cardiovascular disease in autoimmune rheumatic diseases

Autoimmunity Reviews

Volumn 12, Issue 10, 2013, Pages 1004-1015

  Hollan, Ivana ^a   Meroni, Pier Luigi ^b   Ahearn, Joseph M ^c   Cohen Tervaert, J W ^d   Curran, Sam ^e   Goodyear, Carl S ^f   Hestad, Knut A ^g,h   Kahaleh, Bashar ⁱ   Riggio, Marcello ^e   Shields, Kelly ^c   Wasko, Mary C ^c  

^a Hospital for Rheumatic Diseases   (Norway)

^b UNIVERSITY OF MILAN   (Italy)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SINT FRANCISCUS GASTHUIS   (Netherlands)

^e GLASGOW DENTAL HOSPITAL AND SCHOOL   (United Kingdom)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g INNLANDET HOSPITAL TRUST   (Norway)

^h NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

ⁱ MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Atherosclerosis; Immune system; Inflammation; Rheumatic

Indexed keywords

COMPLEMENT COMPONENT C4D; LIPOPROTEIN; PHOSPHOLIPID ANTIBODY;

AORTA ANEURYSM; APOPTOSIS; ARTERIAL STIFFNESS; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNITY; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CONNECTIVE TISSUE DISEASE; DEPRESSION; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; EPIGENETICS; HEART FAILURE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERURICEMIA; HYPOTHYROIDISM; INFLAMMATION; INSULIN RESISTANCE; KIDNEY DISEASE; MICROANGIOPATHY; MYOCARDITIS; OBESITY; PERICARDIUM; PERIODONTAL DISEASE; REVIEW; RHEUMATIC DISEASE; RISK FACTOR; SCLERODERMA; SLEEP DISORDERED BREATHING; SMALL VESSEL VASCULITIS; SYSTEMIC SCLEROSIS; UNDERWEIGHT; VASA VASORUM; VASCULITIS; VITAMIN D DEFICIENCY;

ATHEROSCLEROSIS; IMMUNE SYSTEM; INFLAMMATION; RHEUMATIC;

AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; RHEUMATIC DISEASES;

EID: 84880759365     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.03.013     Document Type: Review

References (143)

1. Zinger H., Sherer Y., Shoenfeld Y. Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings. Clin Rev Allergy Immunol 2009, 37(1):20-28.
2. Sarzi-Puttini P., Atzeni F., Gerli R., Bartoloni E., Doria A., Barskova T., et al. Cardiac involvement in systemic rheumatic diseases: an update. Autoimmun Rev 2010, 9(12):849-852.
3. Nurmohamed M.T. Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev 2009, 8(8):663-667.
4. Ramonda R., Lo N.A., Modesti V., Nalotto L., Musacchio E., Iaccarino L., et al. Atherosclerosis in psoriatic arthritis. Autoimmun Rev 2011, 10(12):773-778.
5. Maradit-Kremers H., Crowson C.S., Nicola P.J., Ballman K.V., Roger V.L., Jacobsen S.J., et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005, 52(2):402-411.
6. Bartoloni E., Alunno A., Bistoni O., Gerli R. How early is the atherosclerotic risk in rheumatoid arthritis?. Autoimmun Rev 2010, 9(10):701-707.
7. Soltesz P., Kerekes G., Der H., Szucs G., Szanto S., Kiss E., et al. Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. Autoimmun Rev 2011, 10(7):416-425.
8. Gremese E., Ferraccioli G. The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev 2011, 10(10):582-589.
9. Tam L.S., Tomlinson B., Chu T.T., Li T.K., Li E.K. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007, 26(9):1495-1498.
10. Wasko M.C., Kay J., Hsia E.C., Rahman M.U. Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. Arthritis Care Res (Hoboken) 2011, 63(4):512-521.
11. Antohe J.L., Bili A., Sartorius J.A., Kirchner H.L., Morris S.J., Dancea S., et al. Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor alpha therapy. Arthritis Care Res (Hoboken) 2012, 64(2):215-221.
12. Kremers H.M., Nicola P.J., Crowson C.S., Ballman K.V., Gabriel S.E. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 2004, 50(11):3450-3457.
13. Cohen Tervaert J.W. Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides. Best Pract Res Clin Rheumatol 2013, 27(1):33-44.
14. Tervaert J.W. Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis. Clin Exp Immunol 2009, 156(3):377-385.
15. Petermann Smits D.R., Wilde B., Kianersi A.M., de J.H., van P.P., Cohen Tervaert J.W. Metabolic syndrome in ANCA-associated vasculitis. Rheumatology (Oxford) 2013, 52(1):197-203.
16. Cervera R., Khamashta M.A., Shoenfeld Y., Camps M.T., Jacobsen S., Kiss E., et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009, 68(9):1428-1432.
17. Cervera R., Piette J.C., Font J., Khamashta M.A., Shoenfeld Y., Camps M.T., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002, 46(4):1019-1027.
18. Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011, 7(6):330-339.
19. Shoenfeld Y., Gerli R., Doria A., Matsuura E., Cerinic M.M., Ronda N., et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005, 112(21):3337-3347.
20. Doria A., Sherer Y., Meroni P.L., Shoenfeld Y. Inflammation and accelerated atherosclerosis: basic mechanisms. Rheum Dis Clin North Am 2005, 31(2):355-362. [viii].
21. Artenjak A., Lakota K., Frank M., Cucnik S., Rozman B., Bozic B., et al. Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review. Autoimmun Rev 2012, 11(12):873-882.
22. Gualtierotti R., Biggioggero M., Meroni P.L. Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome. Clin Rev Allergy Immunol 2013, 44(1):51-56.
23. Nussinovitch U., Shoenfeld Y. Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality. Autoimmun Rev 2011, 10(5):259-266.
24. Ngian G.S., Sahhar J., Wicks I.P., Van D.S. Cardiovascular disease in systemic sclerosis-an emerging association?. Arthritis Res Ther 2011, 13(4):237.
25. Libby P., Crea F. Clinical implications of inflammation for cardiovascular primary prevention. Eur Heart J 2010, 31(7):777-783.
26. Kaptoge S., Di A.E., Lowe G., Pepys M.B., Thompson S.G., Collins R., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375(9709):132-140.
27. Nordestgaard B.G., Zacho J. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?. Nutr Metab Cardiovasc Dis 2009, 19(8):521-524.
28. Winyard P.G., Tatzber F., Esterbauer H., Kus M.L., Blake D.R., Morris C.J. Presence of foam cells containing oxidised low density lipoprotein in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 1993, 52(9):677-680.
29. Pasceri V., Yeh E.T. A tale of two diseases: atherosclerosis and rheumatoid arthritis [editorial; comment]. Circulation 1999, 100(21):2124-2126.
30. Koenig W., Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007, 27(1):15-26.
31. Choi H.K., Hernan M.A., Seeger J.D., Robins J.M., Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359(9313):1173-1177.
32. Jacobsson L.T., Turesson C., Gulfe A., Kapetanovic M.C., Petersson I.F., Saxne T., et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005, 32(7):1213-1218.
33. Dixon W.G., Watson K.D., Lunt M., Hyrich K.L., Silman A.J., Symmons D.P. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007, 56(9):2905-2912.
34. McCarey D.W., Sattar N., McInnes I.B. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?. Arthritis Res Ther 2005, 7(2):55-61.
35. Jain M.K., Ridker P.M. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005, 4(12):977-987.
36. Klingenberg R., Hansson G.K. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J 2009, 30(23):2838-2844.
37. Bacon P.A., Townend J.N. Nails in the coffin: increasing evidence for the role of rheumatic disease in the cardiovascular mortality of rheumatoid arthritis. Arthritis Rheum 2001, 44(12):2707-2710.
38. Hollan I. Vascular inflammation in systemic rheumatic diseases. Curr Med Lit Rheumatol 2011, 30(2):33-45.
39. Aubry M.C., Riehle D.L., Edwards W.D., Maradit-Kremers H., Roger V.L., Sebo T.J., et al. B-Lymphocytes in plaque and adventitia of coronary arteries in two patients with rheumatoid arthritis and coronary atherosclerosis: preliminary observations. Cardiovasc Pathol 2004, 13(4):233-236.
40. Aubry M.C., Maradit-Kremers H., Reinalda M.S., Crowson C.S., Edwards W.D., Gabriel S.E. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 2007, 34(5):937-942.
41. Millonig G., Malcom G.T., Wick G. Early inflammatory-immunological lesions in juvenile atherosclerosis from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY)-study. Atherosclerosis 2002, 160(2):441-448.
42. Wallsh E., Weinstein G.S., Franzone A., Clavel A., Rossi P.A., Kreps E. Inflammation of the coronary arteries in patients with unstable angina. Tex Heart Inst J 1986, 13(1):105-108.
43. Wilcox J.N., Scott N.A. Potential role of the adventitia in arteritis and atherosclerosis. Int J Cardiol 1996, 54:S21-S35. [Suppl.].
44. Higuchi M.L., Gutierrez P.S., Bezerra H.G., Palomino S.A., Aiello V.D., Silvestre J.M., et al. Comparison between adventitial and intimal inflammation of ruptured and nonruptured atherosclerotic plaques in human coronary arteries. Arq Bras Cardiol 2002, 79(1):20-24.
45. Vela D., Buja L.M., Madjid M., Burke A., Naghavi M., Willerson J.T., et al. The role of periadventitial fat in atherosclerosis. Arch Pathol Lab Med 2007, 131(3):481-487.
46. Michel J.B., Thaunat O., Houard X., Meilhac O., Caligiuri G., Nicoletti A. Topological determinants and consequences of adventitial responses to arterial wall injury. Arterioscler Thromb Vasc Biol 2007, 27(6):1259-1268.
47. Hollan I., Prayson R., Saatvedt K., Almdahl S.M., Nossent H.C., Mikkelsen K., et al. Inflammatory cell infiltrates in vessels with different susceptibility to atherosclerosis in rheumatic and non-rheumatic patients. Circ J 2008, 72(12):1986-1992.
48. Hollan I., Scott H., Saatvedt K., Prayson R., Mikkelsen K., Nossent H.C., et al. Inflammatory rheumatic disease and smoking are predictors of aortic inflammation: a controlled study of biopsy specimens obtained at coronary artery surgery. Arthritis Rheum 2007, 56(6):2072-2079.
49. Blockmans D., de Ceuninck L., Vanderschueren S., Knockaert D., Mortelmans L., Bobbaers H. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology (Oxford) 2007, 46(4):672-677.
50. Palazzi C., D' Angelo S., Lubrano E., Olivieri I. Aortic involvement in ankylosing spondylitis. Clin Exp Rheumatol 2008, 26(3 Suppl. 49):S131-S134.
51. Martinez-Valle F., Solans-Laque R., Bosch-Gil J., Vilardell-Tarres M. Aortic involvement in giant cell arteritis. Autoimmun Rev 2010, 9(7):521-524.
52. Hollan I. Vascular inflammation in rheumatic and non-rheumatic patients: a controlled study of biopsy specimens obtained during coronary artery surgery (Feiring Heart Biopsy Study) 2009, 2-48. University of Oslo, Oslo, [Ref Type: Serial (Book,Monograph)].
53. Wanhainen A., Bergqvist D., Boman K., Nilsson T.K., Rutegard J., Bjorck M. Risk factors associated with abdominal aortic aneurysm: a population-based study with historical and current data. J Vasc Surg 2005, 41(3):390-396.
54. Forsdahl S.H., Solberg S., Singh K., Jacobsen B.K. Abdominal aortic aneurysms, or a relatively large diameter of non-aneurysmal aortas, increase total and cardiovascular mortality: the Tromso study. Int J Epidemiol 2010, 39(1):225-232.
55. Hellmann D.B., Grand D.J., Freischlag J.A. Inflammatory abdominal aortic aneurysm. JAMA 2007, 297(4):395-400.
56. Atzeni F., Turiel M., Hollan I., Meroni P., Sitia S., Tomasoni L., et al. Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. Autoimmun Rev 2010, 9(12):845-848.
57. Xiong W., MacTaggart J., Knispel R., Worth J., Persidsky Y., Baxter B.T. Blocking TNF-alpha attenuates aneurysm formation in a murine model. J Immunol 2009, 183(4):2741-2746.
58. Curran S., Riggio M., Hollan I., Lapin D., Murray C., Goodyear C. Heat shock protein 47 expression in the diseased aortic adventitia of patients with and without rheumatoid arthritis. Cardiovascular Rheumatology Meeting 2010 2010, [Ref Type: Abstract].
59. Ahmed A., Hollan I., Mikkelsen K., Førre Ø., McInnes I.B., Goodyear C. The aortic adventitia of coronary bypass patients with rheumatoid arthritis provides a survival niche, and antigen depot, for B cells. Annual Scientific Meeting of American College of Rheumatology 2009, [Ref Type: Abstract].
60. Curran S, Hollan I, Riggio M, Murray C, Goodyear CS, Lapin D. Bacteria in diseased aortic tissue of subjects with and without rheumatoid arthritis. submitted for publication.
61. Marques da S.R., Caugant D.A., Eribe E.R., Aas J.A., Lingaas P.S., Geiran O., et al. Bacterial diversity in aortic aneurysms determined by 16S ribosomal RNA gene analysis. J Vasc Surg 2006, 44(5):1055-1060.
62. Siala M., Gdoura R., Fourati H., Rihl M., Jaulhac B., Younes M., et al. Broad-range PCR, cloning and sequencing of the full 16S rRNA gene for detection of bacterial DNA in synovial fluid samples of Tunisian patients with reactive and undifferentiated arthritis. Arthritis Res Ther 2009, 11(4):R102.
63. Sun W., Dong L., Kaneyama K., Takegami T., Segami N. Bacterial diversity in synovial fluids of patients with TMD determined by cloning and sequencing analysis of the 16S ribosomal RNA gene. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008, 105(5):566-571.
64. Hollan I., Nebuloni M., Bottazzi B., Mikkelsen K., Førre O.T., Almdahl S.M., et al. Pentraxin 3, a novel cardiovascular biomarker, is expressed in aortic specimens of patients with coronary artery disease with and without rheumatoid arthritis. Cardiovasc Pathol Feb 20 2013, http://dx.doi.org/10.1016/j.carpath.2013.01.007 [pii:S1054-8807(13)00020-3, Epub ahead of print].
65. Hollan I., Bottazzi B., Cuccovillo I., Forre O.T., Mikkelsen K., Saatvedt K., et al. Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease. Arthritis Care Res (Hoboken) 2010, 62(3):378-385.
66. Maki-Petaja K.M., Wilkinson I.B. Anti-inflammatory drugs and statins for arterial stiffness reduction. Curr Pharm Des 2009, 15(3):290-303.
67. Shields K.J., Stolz D., Watkins S.C., Ahearn J.M. Complement proteins C3 and C4 bind to collagen and elastin in the vascular wall: a potential role in vascular stiffness and atherosclerosis. Clin Transl Sci 2011, 4(3):146-152.
68. Nicola P.J., Maradit-Kremers H., Roger V.L., Jacobsen S.J., Crowson C.S., Ballman K.V., et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005, 52(2):412-420.
69. Grundtman C., Hollan I., Forre O.T., Saatvedt K., Mikkelsen K., Lundberg I.E. Cardiovascular disease in patients with inflammatory rheumatic disease is associated with up-regulation of markers of inflammation in cardiac microvessels and cardiomyocytes. Arthritis Rheum 2010, 62(3):667-673.
70. Recio-Mayoral A., Mason J.C., Kaski J.C., Rubens M.B., Harari O.A., Camici P.G. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur Heart J 2009, 30(15):1837-1843.
71. Raza K., Kitas G.D. Reversing myocardial microvascular disease in a patient with rheumatoid arthritis. J Rheumatol 2005, 32(4):754-756.
72. Kotyla P.J., Owczarek A., Rakoczy J., Lewicki M., Kucharz E.J., Emery P. Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: assessment of heart function by echocardiography, endothelin 1, interleukin 6, and NT-pro brain natriuretic peptide. J Rheumatol 2012, 39(4):701-706.
73. Wolfe F., Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy*1. Am J Med 2004, 116(5):305-311.
74. Myasoedova E., Crowson C.S., Nicola P.J., Maradit-Kremers H., Davis J.M., Roger V.L., et al. The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol 2011, 38(8):1601-1606.
75. Langheinrich A.C., Kampschulte M., Buch T., Bohle R.M. Vasa vasorum and atherosclerosis - Quid novi?. Thromb Haemost 2007, 97(6):873-879.
76. Orasanu G., Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 2009, 53(5 Suppl.):S35-S42.
77. Numano F. Vasa vasoritis, vasculitis and atherosclerosis. Int J Cardiol 2000, 75(Suppl. 1):S1-S8.
78. Aghamohammadzadeh R., Withers S., Lynch F., Greenstein A., Malik R., Heagerty A. Perivascular adipose tissue from human systemic and coronary vessels: the emergence of a new pharmacotherapeutic target. Br J Pharmacol 2012, 165(3):670-682.
79. Iacobellis G., Malavazos A.E., Corsi M.M. Epicardial fat: from the biomolecular aspects to the clinical practice. Int J Biochem Cell Biol 2011, 43(12):1651-1654.
80. Ohman M.K., Luo W., Wang H., Guo C., Abdallah W., Russo H.M., et al. Perivascular visceral adipose tissue induces atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis 2011, 219(1):33-39.
81. Ding J., Hsu F.C., Harris T.B., Liu Y., Kritchevsky S.B., Szklo M., et al. The association of pericardial fat with incident coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Clin Nutr 2009, 90(3):499-504.
82. Lehman S.J., Massaro J.M., Schlett C.L., O'Donnell C.J., Hoffmann U., Fox C.S. Peri-aortic fat, cardiovascular disease risk factors, and aortic calcification: the Framingham Heart Study. Atherosclerosis 2010, 210(2):656-661.
83. Mahabadi A.A., Reinsch N., Lehmann N., Altenbernd J., Kalsch H., Seibel R.M., et al. Association of pericoronary fat volume with atherosclerotic plaque burden in the underlying coronary artery: a segment analysis. Atherosclerosis 2010, 211(1):195-199.
84. Giles J.T., Allison M., Blumenthal R.S., Post W., Gelber A.C., Petri M., et al. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum 2010, 62(11):3173-3182.
85. Mallat Z., Tedgui A. Apoptosis in the vasculature: mechanisms and functional importance. Br J Pharmacol 2000, 130(5):947-962.
86. Assaly R., Olson D., Hammersley J., Fan P.S., Liu J., Shapiro J.I., et al. Initial evidence of endothelial cell apoptosis as a mechanism of systemic capillary leak syndrome. Chest 2001, 120(4):1301-1308.
87. van P.P., Duijvestijn A., Debrus-Palmans L., Damoiseaux J., Vroomen M., Tervaert J.W. Induction of endothelial cell apoptosis by IgG antibodies from SLE patients with nephropathy: a potential role for anti-endothelial cell antibodies. Ann N Y Acad Sci 2007, 1108:147-156.
88. Sgonc R., Gruschwitz M.S., Dietrich H., Recheis H., Gershwin M.E., Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996, 98(3):785-792.
89. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007, 35(4):495-516.
90. Bird A. Perceptions of epigenetics. Nature 2007, 447(7143):396-398.
91. Wang Y., Fan P.S., Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006, 54(7):2271-2279.
92. Webster A.L., Yan M.S., Marsden P.A. Epigenetics and cardiovascular disease. Can J Cardiol 2013, 29(1):46-57.
93. Mattila K.J., Pussinen P.J., Paju S. Dental infections and cardiovascular diseases: a review. J Periodontol 2005, 76(11 Suppl.):2085-2088.
94. Bahekar A.A., Singh S., Saha S., Molnar J., Arora R. The prevalence and incidence of coronary heart disease is significantly increased in periodontitis: a meta-analysis. Am Heart J 2007, 154:830-837.
95. Gibson F.C., Hong C., Chou H.H., Yumoto H., Chen J., Lien E., et al. Innate immune recognition of invasive bacteria accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004, 109(22):2801-2806.
96. Tonetti M.S. Periodontitis and risk for atherosclerosis: an update on intervention trials. J Clin Periodontol 2009, 36(Suppl. 10):15-19.
97. Janssen K.M., Vissink A., de Smit M.J., Westra J., Brouwer E. Lessons to be learned from periodontitis. Curr Opin Rheumatol 2013, 25(2):241-247.
98. Mercado F.B., Marshall R.I., Klestov A.C., Bartold P.M. Relationship between rheumatoid arthritis and periodontitis. J Periodontol 2001, 72(6):779-787.
99. Moen K., Brun J.G., Valen M., Skartveit L., Eribe E.K., Olsen I., et al. Synovial inflammation in active rheumatoid arthritis and psoriatic arthritis facilitates trapping of a variety of oral bacterial DNAs. Clin Exp Rheumatol 2006, 24(6):656-663.
100. Ogrendik M., Kokino S., Ozdemir F., Bird P.S., Hamlet S. Serum antibodies to oral anaerobic bacteria in patients with rheumatoid arthritis. MedGenMed 2005, 7(2):2.
101. Ramamurthy N.S., Greenwald R.A., Celiker M.Y., Shi E.Y. Experimental arthritis in rats induces biomarkers of periodontitis which are ameliorated by gene therapy with tissue inhibitor of matrix metalloproteinases. J Periodontol 2005, 76(2):229-233.
102. Ortiz P., Bissada N.F., Palomo L., Han Y.W., Al-Zahrani M.S., Panneerselvam A., et al. Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors. J Periodontol 2009, 80(4):535-540.
103. Liao F., Li Z., Wang Y., Shi B., Gong Z., Cheng X. Porphyromonas gingivalis may play an important role in the pathogenesis of periodontitis-associated rheumatoid arthritis. Med Hypotheses 2009, 72(6):732-735.
104. Serrano C.V., Setani K.T., Sakamoto E., Andrei A.M., Fraguas R. Association between depression and development of coronary artery disease: pathophysiologic and diagnostic implications. Vasc Health Risk Manag 2011, 7:159-164.
105. Frasure-Smith N., Lesperance F. Depression and cardiac risk: present status and future directions. Heart 2010, 96(3):173-176.
106. Margaretten M., Julian L., Katz P., Yelin E. Depression in patients with rheumatoid arthritis: description, causes and mechanisms. Int J Clin Rheumatol 2011, 6(6):617-623.
107. Maes M., Ringel K., Kubera M., Berk M., Rybakowski J. Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. J Affect Disord 2012, 136(3):386-392.
108. Clark I.A., Alleva L.M., Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol Ther 2010, 128(3):519-548.
109. Sluzewska A., Samborski W., Sobieska M., Klein R., Bosmans E. Serotonin Antibodies in Relation to Immune Activation in Major Depression. Hum Psychopharmacol 1997, 12:453-458.
110. Galeazzi M., Annunziata P., Sebastiani G.D., Bellisai F., Campanella V., Ferrara G.B., et al. Anti-ganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus: clinical, serological, and HLA class II gene associations. European Concerted Action on the Immunogenetics of SLE. J Rheumatol 2000, 27(1):135-141.
111. Tomfohr L.M., Murphy M.L., Miller G.E., Puterman E. Multiwave associations between depressive symptoms and endothelial function in adolescent and young adult females. Psychosom Med 2011, 73(6):456-461.
112. Steptoe A., Strike P.C., Perkins-Porras L., McEwan J.R., Whitehead D.L. Acute depressed mood as a trigger of acute coronary syndromes. Biol Psychiatry 2006, 60(8):837-842.
113. Tynan R.J., Weidenhofer J., Hinwood M., Cairns M.J., Day T.A., Walker F.R. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun 2012, 26(3):469-479.
114. Wozniak G., Toska A., Saridi M., Mouzas O. Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis. Med Sci Monit 2011, 17(9):RA205-RA214.
115. Scherrer J.F., Garfield L.D., Lustman P.J., Hauptman P.J., Chrusciel T., Zeringue A., et al. Antidepressant drug compliance: reduced risk of MI and mortality in depressed patients. Am J Med 2011, 124(4):318-324.
116. Hestad K.A., Tonseth S., Stoen C.D., Ueland T., Aukrust P. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT 2003, 19(4):183-188.
117. Moylan S., Eyre H.A., Maes M., Baune B.T., Jacka F.N., Berk M. Exercising the worry away: how inflammation, oxidative and nitrogen stress mediates the beneficial effect of physical activity on anxiety disorder symptoms and behaviours. Neurosci Biobehav Rev 2013, 37(4):573-584.
118. Maes M., Fisar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012, 20(3):127-150.
119. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367(9504):29-35.
120. Menter A., Augustin M., Signorovitch J., Yu A.P., Wu E.Q., Gupta S.R., et al. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol 2010, 62(5):812-818.
121. Westhovens R., Cole J.C., Li T., Martin M., Maclean R., Lin P., et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology (Oxford) 2006, 45(10):1238-1246.
122. Han C., Smolen J.S., Kavanaugh A., van der Heijde D., Braun J., Westhovens R., et al. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res Ther 2007, 9(5):R103.
123. Lichtman J.H., Bigger J.T., Blumenthal J.A., Frasure-Smith N., Kaufmann P.G., Lesperance F., et al. AHA science advisory. Depression and coronary heart disease. Recommendations for screening, referral, and treatment. A science advisory from the American Heart Association Prevention Committee to the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care Outcomes Research. Endorsed by the American Psychiatric Association. Prog Cardiovasc Nurs 2009, 24(1):19-26.
124. Tongers J., Roncalli J.G., Losordo D.W. Role of endothelial progenitor cells during ischemia-induced vasculogenesis and collateral formation. Microvasc Res 2010, 79(3):200-206.
125. Daoussis D., Kitas G.D. Uric acid and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford) 2011, 50(8):1354-1355.
126. McCoy S.S., Crowson C.S., Gabriel S.E., Matteson E.L. Hypothyroidism as a risk factor for development of cardiovascular disease in patients with rheumatoid arthritis. J Rheumatol 2012, 39(5):954-958.
127. Gatenby P., Lucas R., Swaminathan A. Vitamin D deficiency and risk for rheumatic diseases: an update. Curr Opin Rheumatol 2013, 25(2):184-191.
128. Smolders J., Peelen E., Thewissen M., Cohen Tervaert J.W., Menheere P., Hupperts R., et al. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One 2010, 5(12):e15235.
129. Welsh P., Peters M.J., McInnes I.B., Lems W.F., Lips P.T., McKellar G., et al. Vitamin D deficiency is common in patients with RA and linked to disease activity, but circulating levels are unaffected by TNFalpha blockade: results from a prospective cohort study. Ann Rheum Dis 2011, 70(6):1165-1167.
130. Walsh J.A., Duffin K.C., Crim J., Clegg D.O. Lower frequency of obstructive sleep apnea in spondyloarthritis patients taking TNF-inhibitors. J Clin Sleep Med 2012, 8(6):643-648.
131. Bartoloni E., Alunno A., Bistoni O., Gerli R. Cardiovascular risk in rheumatoid arthritis and systemic autoimmune rheumatic disorders: a suggested model of preventive strategy. Clin Rev Allergy Immunol 2013, 44(1):14-22.
132. Peters M.J., Symmons D.P., McCarey D., Dijkmans B.A., Nicola P., Kvien T.K., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69(2):325-331.
133. Myasoedova E., Gabriel S.E. Cardiovascular disease in rheumatoid arthritis: a step forward. Curr Opin Rheumatol 2010, 22(3):342-347.
134. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007, 14(Suppl. 2):S1-S113.
135. McCarey D.W., McInnes I.B., Madhok R., Hampson R., Scherbakov O., Ford I., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004, 363(9426):2015-2021.
136. de Jong H.J., Klungel O.H., van D.L., Vandebriel R.J., Leufkens H.G., van der Laan J.W., et al. Use of statins is associated with an increased risk of rheumatoid arthritis. Ann Rheum Dis 2012, 71(5):648-654.
137. de Jong H.J., Saldi S.R., Klungel O.H., Vandebriel R.J., Souverein P.C., Meyboom R.H., et al. Statin-associated polymyalgia rheumatica. An analysis using WHO global individual case safety database: a case/non-case approach. PLoS One 2012, 7(7):e41289.
138. de Jong H.J., Tervaert J.W., Saldi S.R., Vandebriel R.J., Souverein P.C., Meyboom R.H., et al. Association between statin use and lupus-like syndrome using spontaneous reports. Semin Arthritis Rheum 2011, 41(3):373-381.
139. Vandebriel R.J., de Jong H.J., Gremmer E.R., Klungel O.H., Tervaert J.W., Slob W., et al. Statins accelerate the onset of collagen type II-induced arthritis in mice. Arthritis Res Ther 2012, 14(2):R90.
140. Chighizola C.B., Favalli E.G., Meroni P.L. Novel mechanisms of action of the biologicals in rheumatic diseases. Clin Rev Allergy Immunol Jan 24 2013, [Epub ahead of print, PubMed PMID: 23345026].
141. Wasko M.C., Dasgupta A., Hubert H., Fries J.F., Ward M.M. Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum 2013, 65(2):334-342.
142. Westlake S.L., Colebatch A.N., Baird J., Curzen N., Kiely P., Quinn M., et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2011, 50(3):518-531.
143. Kerekes G., Soltesz P., Der H., Veres K., Szabo Z., Vegvari A., et al. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann N Y Acad Sci 2009, 1173:814-821.